trans-2-chloroacetamido-1,2,3,4-tetrahydronaphthalen-1-ol | 92471-25-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: trans-2-chloroacetamido-1,2,3,4-tetrahydronaphthalen-1-ol
• 英文别名: 2-chloro-N-((1RS,2RS)-trans-1-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-acetamide；2-Chloro-N-[(1S,2S)-1-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]acetamide
• CAS: 92471-25-5
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.702
• InChiKey: AIXWNVRSWWTTCD-JQWIXIFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-2-chloroacetamido-1,2,3,4-tetrahydronaphthalen-1-ol 在 盐酸 、 sodium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 水 、 异丙醇 为溶剂， 反应 5.0h， 生成 trans-2,3,4a,5,6,10b-hexahydro-4H-naphth<1,2b><1,4>oxazine
  参考文献：
  名称：

  Dykstra; Hazelhoff; Mulder, European Journal of Medicinal Chemistry, 1985, vol. 20, # 3, p. 247 - 250

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-chloroacetamido)-3,4-dihydronaphthalen-1(2H)-one 在 sodium borohydrid 、 溶剂黄146 作用下， 以 乙醇 、 氯仿 为溶剂， 以1.7 g (71%)的产率得到trans-2-chloroacetamido-1,2,3,4-tetrahydronaphthalen-1-ol
  参考文献：
  名称：

  Hexahydronaphth[1,2-b]-1,4-oxazines

  摘要：

  六氢萘并[1,2-b]-1,4-噁唑具有多巴胺能活性，并表现出.alpha..sub.2-肾上腺素受体拮抗作用。它们在帕金森病、抑郁症和高血压的治疗中很有用。一种重要的制备方法是通过环合成适当的2-氯乙酰胺四氢萘酚-1-醇，并还原所得的环状酰胺羰基团。

  公开号：

  US04420480A1

文献信息

• Synthesis and Absolute Configurations of Hexahydro-Naphthoxazines as Rigid Congeners of Phenmetrazine
  作者：Roberto Perrone、Giancarlo Bettoni、Vincenzo Tortorella

  DOI：10.1002/ardp.19833160707

  日期：——

  As part of a project concerned with the synthesis of rigid congeners of adrenergic drugs, some naphthoxazines, cis and trans isomers of 2,3,4a,5,6,10b‐hexahydro‐4H‐naphth[1,2‐b][1,4]oxazine (1) and cis and trans isomers of its isoster 2,3,4a,5,6,10b‐hexahydro‐1H‐naphth[2,1‐b][1,4]oxazine (2) were prepared. The absolute configurations of these compounds were determined by means of chemical correlation

  作为与肾上腺素能药物刚性同系物合成项目的一部分，一些萘并恶嗪、2,3,4a, 5,6,10b-六氢-4H-萘 [1,2-b] [1] 的顺式和反式异构体, 4] 恶嗪 (1) 及其异构体 2,3,4a, 5,6,10b-六氢-1H-萘 [2,1-b] [1,4] 恶嗪 (2) 的顺反异构体的制备. 这些化合物的绝对构型是通过化学相关性和手性特性的测定来确定的。
• 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES
  申请人：Fukunaga Kenji

  公开号：US20090233918A1

  公开（公告）日：2009-09-17

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R 2 represents a hydrogen or the like; R 3 represents methyl group or the like; R 20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R 4 represents hydrogen or the like; R 5 represents hydrogen or the like; R 6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH 2 , oxygen atom, NH, or the like; any one or more of R 5 and R 6 , R 5 and R 4 , R 6 and R 4 , X and R 5 , X and R 4 , X and R 6 , and R 6 and R 6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体或药物可接受的盐：其中，R2代表氢或类似物；R3代表甲基基团或类似物；R20代表卤素原子或类似物；q表示0到3的整数；Z代表氮原子，CH或类似物；R4代表氢或类似物；R5代表氢或类似物；R6代表取代的烷氧基或类似物；p表示0到3的整数；X代表键，CH2，氧原子，NH或类似物；R5和R6，R5和R4，R6和R4，X和R5，X和R4，X和R6以及R6和R6中的任何一个或多个可以结合形成环，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（例如阿尔茨海默病）。
• Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them
  申请人：Merck & Co., Inc.

  公开号：EP0080115A2

  公开（公告）日：1983-06-01

  Hexahydronaphth[1,2-b]-1,4-oxazines have dopaminergic activity and display α2-adrenergic receptor antagonism. They are useful in the treatment of parkinsonism, depression and hypertension. An important method of preparation is by ring closure of the appropriate 2-chloroacetamido- tetrahydronaphthalen-1-ol and reduction of the resulting cyclic amide carbonyl group.

  六氢萘并[1,2-b]-1,4-噁嗪具有多巴胺能活性，并显示出α2-肾上腺素能受体拮抗作用。 它们可用于治疗帕金森病、抑郁症和高血压。 一种重要的制备方法是将适当的 2-氯乙酰胺基四氢萘-1-醇闭环，并还原由此产生的环状酰胺羰基。
• 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2423207A2

  公开（公告）日：2012-02-29

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R3 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  式 (I) 所代表的化合物、其光学活性异构体或其药用盐： 其中 R2 代表氢或类似物；R3 代表甲基或类似物；R20 代表卤原子或类似物；q 代表 0 至 3 的整数；Z 代表氮原子、CH 或类似物；R4 代表氢或类似物；R5 代表氢或类似物；R6 代表取代的烷氧基或类似物；p 代表 0 至 3 的整数；X代表键、CH2、氧原子、NH或类似物；R5和R6、R5和R4、R6和R4、X和R5、X和R4、X和R6、R3和R6中的任意一个或多个可相互结合形成环，用于预防和/或治疗由tau蛋白激酶1亢进引起的疾病，如神经退行性疾病（如阿尔茨海默病）。如阿尔茨海默病）。
• WO2007/119463
  申请人：——

  公开号：——

  公开（公告）日：——